MultimericLigands™ – Higher Activity – Lower Endotoxin

AdipoGen Life Sciences’ Multimeric Proteins are high activity constructs in which two trimeric TNFSF ligands are linked via the oligomeric collagen domain of ACRP30 [ACRP30headless] and therefore mimic the membrane-bound forms of the proteins.

The Largest Panel of Ultrapotent Multimeric Ligands™
Equivalent to MegaLigands!

Endogenous TNF superfamily ligands are either active as membrane-form (e.g. FasL, TRAIL, CD40L, OX40L) or are secreted and activated through oligomerisation by the binding of proteoglycans at the surface of cells (e.g. APRIL). The oligomerisation is triggered
• by fusing the TNF superfamily ligands to the collagen domain of the protein ACRP30 (which itself has no functional activity) to form a hexameric structure and therefore creating “Multimeric Proteins”, or
• by adding a cross-linking antibody called “TNF Ligands Enhancer” (Prod. No. AG-35B-0001).

Multimeric FasL™ [MegaFasL™]

FasL (human) (multimeric) (rec.)

AG-40B-0130-C010 – 10 μg
AG-40B-0130-3010 – 3 x 10 μg (MultiPack)

• Multimeric FasL™ very effectively simulates the natural membrane-assisted aggregation of FasL in vivo.

Source: HEK 293 cells.
Sequence: Human FasL (aa 139-281) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag.
Specificity: Binds to human and mouse Fas.
Biological Activity: Induces apoptosis of human JurkatT cells at a concentration of <1ng/ml.
Endotoxin Content: <0.02EU/μg purified protein (LAL test; Lonza).

Literature References:
• Two adjacent trimeric Fas ligands are required for Fassignaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003)
• A Fas agonist induces high levels of apoptosisin haematological malignancies: P. Greaney, et al.; Leuk. Res. 30, 415 (2006) MultimericFasL

Figure: Oligomerisation of FasL (human) efficiently triggers Jurkat cell death.

Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (AG-40B-0130), Fc (human):FasL (human) (rec.) (AG-40B-0132), FasL (human) (rec.) (AG-40B-0001) or FasL (human) (rec.) + Enhancer (AG-44B-0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (FasL (human) (multimeric), Fc (human):FasL (human) and FasL (human) + Enhancer) kill Jurkat cells at IC50 <0.2ng/ml.

Multimeric CD40L™

CD40L (human) (multimeric) (rec.)

AG-40B-0010-C010 10 μg
AG-40B-0010-3010 MultiPack 3 x 10 μg

• MultimericCD40L™ very effectively mimics the natural membrane-assisted aggregation of CD40L. It is the most potent alternative to activate CD40. No enhancer is required.

• MultimericCD40L™ is a potent B cell activator.

Literature References:
• IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001)

Figure: CD40L (human) (multimeric) (rec.) (Prod. No. AG-40B-0010) does not need an enhancer to induce B cells activation.

Full Panel of Multimeric Ligands™

Originally posted by Adipogen on: https://adipogen.com/multimeric-ligands

Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.